Prior to leading Bresotec, Bloch was CEO and chairman of Bionik Laboratories Corp (OTCMKTS:BNKL), a prosthetics company based in Toronto. He’s also held senior management roles at Sanofi-Aventis Canada, Intellivax International Inc., Gennum Corporation and Tribute Pharmaceuticals.
"We welcome Peter to the InnoCan Board,” CEO Iris Bincovich said in a statement. “Peter's unique combination of experience as an officer of mature companies and as the leader of start up companies along with his extensive healthcare/biotech background will be an invaluable resource for InnoCan.
Also, North America is a top market for InnoCan Pharma and Peter will be a key advisor as we enter 2020 implementing our full commercialization strategy," Bincovich added.
Bloch replaces outgoing director Daryl Fridhandler, who resigned this week. Eyal Flom, another director, has taken on Fridhandler’s role as corporate secretary.
InnoCan Pharma, based in Israel, is developing a platform that enables the controlled release of CBD using injections of liposomes, a vesicle with a structure that resembles cell membranes.
Shares in Canada surged 22.22% to C$0.11.
---Updates for share price---
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel